Program
ibramvibart
Also written as “VYD2311”, “VYD2311-SD” and “VYD2311-MD”.
Its studies are mostly in COVID-19 · Post-Acute COVID-19 Syndrome, led by Invivyd.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Invivyd | 43 open or running | phase 3since Dec 18, 2025 | Jul 18, 2024 | Jun 2027phase 2 · NCT07899346 |
Also a collaborator on its studies: novotech-australia-pty-limited.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 18, 2024First study: phase 1 study in COVID-19First studyNCT06523153 · 40 enrolled · Australia
- Dec 18, 2025Phase 3 study in COVID-19Phase 3 reachedNCT07298434 · 1,770 enrolled · United States
- Jun 8, 2026Phase 3 study in COVID-19NCT07655180 · 210 enrolled · United States
- Oct 20, 2026Phase 2 study in Post-Acute COVID-19 SyndromeNCT07899346 · 130 planned
Ahead
- Jun 2027Primary completion: phase 2 study in Post-Acute COVID-19 SyndromeNCT07899346
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07899346Post-Acute COVID-19 Syndrome | 2 | Not yet recruiting | Jun 2027 | 130 |
| NCT07655180COVID-19 · United States | 3 | Completed | Aug 15, 2026 | 210 |
| NCT07298434COVID-19 · United States | 3 | Active, not recruiting | Aug 2026 | 1,770 |
| NCT06523153COVID-19 · Australia | 1 | Active, not recruiting | May 2025 | 40 |
How it is read
Names in the registry
- “VYD2311”, 3 entries
- “VYD2311-SD”, 1 entry
- “VYD2311-MD”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 3 studies
- Post-Acute COVID-19 Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.